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Abstract 
Background   
Respiratory virus infections are commonly associated with COPD exacerbations but 
little is known about the mechanisms linking virus infection to exacerbations. 
Pathogenic mechanisms in stable COPD include oxidative and nitrosative stress and 
reduced activity of histone deacetylase-2 (HDAC2) but their roles in COPD 
exacerbations is unknown. We investigated oxidative/nitrosative stress and HDAC2 
in COPD exacerbations using experimental rhinovirus infection.  
Methods  
9 subjects with COPD (GOLD stage II), 10 smokers and 11 non-smokers were 
successfully infected with rhinovirus. Markers of oxidative and nitrosative-stress 
associated cellular damage, inflammatory mediators and proteases were measured 
in sputum, and HDAC2 activity measured in sputum and bronchoalveolar 
macrophages. In an in vitro model monocyte derived THP-1 cells were infected with 
rhinovirus and nitrosylation and activity of HDAC2 measured.  
Results 
Rhinovirus infection induced significant increases i  airways inflammation and 
markers of oxidative and nitrosative stress in COPD subjects. Oxidative/nitrosative 
stress markers correlated with virus load and inflammatory markers. Macrophage 
HDAC2 activity was reduced during exacerbation and correlated inversely with virus 
load, inflammatory markers and nitrosative stress. Sputum macrophage HDAC2 
activity pre-infection was inversely associated with sputum virus load and 
inflammatory makers during exacerbation. Rhinovirus infection of monocytes 
induced nitrosylation of HDAC2 and reduced HDAC2 activity, inhibition of 
oxidative/nitrosative stress inhibited rhinovirus-induced inflammatory cytokines.  
Page 4 of 63
ScholarOne - http://mchelp.manuscriptcentral.com/gethelpnow/index.html - (434) 964-4100
CHEST
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Privileged Communication
- 5 - 
 
Conclusions  
Oxidative and nitrosative stress, airways inflammation and impaired HDAC2 may be 
important mechanisms of virus-induced COPD exacerbations. Therapies targeting 
these mechanisms offer potential new treatments for COPD exacerbations. 
 
 
Abbreviations List 
3-NT   3-nitrotyrosine 
8-OHdG  8-hydroxy-2’-deoxyguanosine 
ATS   American Thoracic Society 
COPD   Chronic obstructive pulmonary disease  
ERS   European Respiratory Society 
FEV1   Forced expiratory volume in 1 second 
FVC   Forced vital capacity 
GM-CSF  Granulocyte-macrophage colony stimulating factor 
GOLD   Global Initiative for Obstructive Lung Disease 
HDAC2  Histone deacetylase-2  
IL-   Interleukin 
MMP-9  Matrix metalloprotease-9 
NAC   N-acetylcysteine 
NE   Neutrophil elastase 
RNS   Reactive nitrogen species  
ROS   Reactive oxygen species  
TCID50  Tissue culture infective dose50  
TNF-α   Tumour necrosis factor-alpha 
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Introduction 
Chronic obstructive pulmonary disease (COPD) is a rapidly growing global 
epidemic1. COPD exacerbations cause impaired quality of life, accelerated loss of 
lung function, and enormous healthcare costs2. Most exacerbations are a 
consequence of viral and/or bacterial infections, the most common viruses identified 
are rhinoviruses3 but the mechanisms of virus-induced exacerbations remain 
unclear4. Current therapies for exacerbations consist of corticosteroids and 
antibiotics but these are not very effective, have frequent adverse effects and are 
focused on bacterial exacerbations5,6. New treatments are urgently needed and 
developing these requires a better understanding of the mechanisms of COPD 
exacerbations.  
Pathogenic mechanisms in stable COPD include oxidative and nitrosative stress and 
reduced expression of the anti-inflammatory enzyme histone deacetylase-2 
(HDAC2)7-9. High levels of reactive oxygen species (ROS) and reactive nitrogen 
species (RNS) are generated in COPD resulting in induction of pro-inflammatory 
cytokines and chemokines, mucous hypersecretion, activation of proteases and 
damage to cellular components10. Histone deacetylases remove acetyl groups on 
histones and influence gene expression. HDAC2 suppresses inflammatory gene 
expression and is reduced in alveolar macrophages and lung tissue in COPD, and 
this is believed to be a key mechanism of corticosteroid resistance in COPD8,11. 
Nitrosylation of tyrosine residues on HDAC2 by peroxynitrite results in its 
inactivation12 and ROS activate phosphoinositide 3-kinase leading to 
phosphorylation and inactivation of HDAC213. Therefore oxidative and nitrosative 
stress exert pro-inflammatory effects both through direct induction of inflammatory 
mediators and reduction of the anti-inflammatory action of HDAC2. 
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The roles of oxidative and nitrosative stress and HDAC2 in COPD exacerbations are 
unclear. We have previously demonstrated that experimental rhinovirus infection 
induces symptoms, airflow obstruction and airways inflammation in COPD subjects14-
16. We hypothesized that oxidative and nitrosative stress are increased and HDAC2 
activity reduced in virus-induced COPD exacerbations.  
 
Methods 
Study design 
Ethical approval for the study was obtained from St Mary’s Local Research Ethics 
Committee (study number 07/H0712/138) and informed consent obtained from all 
subjects. COPD subjects (GOLD stage II) and smokers with normal lung function 
were recruited according the criteria established in our previous study 
(Supplementary Table 1)15, together with non-smokers with normal lung function. 
The COPD patients were receiving no inhaled corticosteroids, long-acting regular 
bronchodilators or oral corticosteroids. Baseline samples of induced sputum and 
bronchoalveolar lavage were obtained approximately 14 days prior to infection and 
subjects were inoculated with 10 TCID50 of rhinovirus 16 on day 0 as described 
previously15. Sputum sampling was repeated on subsequent visits on days 3, 5, 9, 
12, 15, 21, and 42 post-infection and bronchoscopy on day 7. Respiratory symptoms 
were recorded daily using diary cards as per our previous studies. A COPD 
exacerbation was defined as an increase in the total lower respiratory score of at 
least 2 points over baseline for at least 2 consecutive days. 
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Sputum assessments 
8-hydroxy-2’-deoxyguanosine (8-OHdG), a marker of hydroxyl radical damage to 
DNA, 8-isoprostane, a marker of lipid peroxidation and 3-nitrotyrosine (3-NT) a 
product of tyrosine nitration mediated by peroxynitrite were measured in sputum 
supernatants using commercially available enzyme immunoassays (Cayman 
Chemical, Ann Arbor, MI, USA) according to the manufacturer’s instructions. Sputum 
nitrite levels were measured using the Griess assay. The Meso Scale Discovery 
(MSD) platform (Maryland, USA) was used to measure inflammatory mediators in 
sputum and bronchoalveolar lavage supernatants. The mediators measured were 
the pro-inflammatory cytokines IL-1β, TNF-α, and GM-CSF, the neutrophil 
chemokine CXCL8/IL-8 and the protease matrix metalloprotease-9 (MMP-9). 
Neutrophil elastase was measured using an enzyme-linked immunosorbent assay 
according to the manufacturers’ instructions (Immunodiagnostik, Benshein, 
Germany). Further details are provided in the e-Appendix.   
 
HDAC2 immunoprecipitation and activity 
The HDAC2 isoenzyme was isolated from macrophage pellets obtained from sputum 
and bronchoalveolar lavage samples. Immunoprecipitation using a HDAC2 antibody 
(Insight Biotect, UK) and PureProteome® Protein A magnetic beads (Millipore, USA) 
was performed.  HDAC activity was measured using a HDAC activity assay (Cayman 
Chemicals, USA) the details of which are provided in the e-Appendix. 
Details of the experimental protocols of the in vitro infection of THP-1 cells (a human 
monocyte cell line) to further investigate the effects of rhinovirus infection on HDAC2 
are provided in the e-Appendix.  
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Statistical analysis 
Data are presented as either means or median, changes from baseline were 
analysed using repeated measures ANOVA or Friedman’s test and differences 
between groups using Holm-Sidak’s multiple comparisons test or the Kruskal-
Wallace test. Correlations between data sets were examined using Spearman's rank 
correlation coefficient. Correlations were examined using peak post-inoculation 
values as in a dynamic and evolving clinical event such as a respiratory infection the 
temporal relationships between the induction of the different markers was variable 
between individual subjects, and using set days may miss relationships where timing 
of events varied. Differences were considered significant for all statistical tests at P 
values of less than 0.05. All reported P values are two-sided. Analysis was 
performed using GraphPad Prism version 6.00 for Windows (GraphPad Software, 
San Diego USA). 
 
Results 
Study subjects 
The clinical characteristics of the subjects successfully infected with rhinovirus 16 
are shown in Table 1. Subjects were age and sex matched between the COPD 
subjects and both control groups, but the non-smokers were older than the smoking 
controls. Cigarette smoke exposure between smoking controls and COPD subjects 
was matched for pack year history.  
 
Clinical and inflammatory responses  
Symptoms and lung function: All COPD subjects experienced an exacerbation 
following rhinovirus infection (e-Figure 1)15. All exacerbations were Level I according 
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to the ATS/ERS severity classification17. FEV1 fell significantly from baseline in the 
COPD subjects on days 3, 5 (P<0.05), 9 (P<0.01), 12 (P<0.05) and 15 (P<0.01), 
with a maximum fall of 250mL (12.92%) on day 15. There were no significant falls 
from baseline in FEV1 in the control groups (e-Figure 2).  
Sputum inflammatory cells, neutrophil elastase and virus load: In the COPD 
subjects sputum inflammatory cells were significantly increased over baseline on day 
9, and were significantly higher compared to the non-smokers on days 9 and 15 
(Figure 1a). There was no significant change from baseline in the smokers and the 
non-smokers. Sputum neutrophils increased significantly from baseline in the COPD 
subjects on day 9 and were significantly higher compared to the smokers on day 12 
(Figure 1b). There were no significant changes in numbers of neutrophils in either 
control group, nor in numbers of macrophages, lymphocytes, or eosinophils in any 
group. Levels of neutrophil elastase in sputum increased from baseline on days 9 
and 15 in the COPD subjects and were significantly higher in the COPD group 
compared to controls on day 5(Figure 1c). 
Sputum virus load was increased from baseline on days 3–15 in the COPD subjects, 
on days 5 and 9 in the smokers and on days 3 and 9 in non-smokers (Figure 1d). 
Sputum virus load was significantly higher in the COPD group compared to both 
control groups on day 12 and compared to the non-smokers on day 15.  
Sputum inflammatory mediators: In the COPD subjects there were significant 
increases from baseline in IL-1β, GM-CSF, CXCL8/IL-8, TNF-α, and MMP-9 in 
sputum (Figure 2). There was no significant induction of inflammatory mediators in 
the non-COPD subjects apart from IL-1β on day 9 and GM-CSF on day 21 in the 
smokers. Sputum mediator levels were significantly higher in the COPD subjects 
compared to the non-smokers on days 9 and 15 and for some mediators on days 5, 
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12, and 21. Levels of inflammatory mediators in bronchoalveolar lavage both at 
baseline and post-inoculation were generally lower than in sputum and are shown in 
the Supplementary Index. Correlations between sputum inflammatory mediators, 
inflammatory cells and virus load in the COPD subjects are shown in Table 2. 
Oxidative and nitrosative stress: Prior to infection sputum 8-OHdG levels were 
higher in the COPD group compared to the smokers (P<0.05) and 3-NT levels were 
higher in the COPD group compared to both non-smokers (P<0.05) and smokers 
(P<0.001), with no differences between the groups in baseline levels of nitrite or 8-
isoprostane (Figure 3). Markers of oxidative and nitrosative stress were all 
significantly induced following rhinovirus infection in COPD subjects with much 
smaller induction seen in the smokers and were significantly higher in the COPD 
subjects compared to the non-COPD subjects (Figure 3 a-d).  
 
Macrophage HDAC2 activity  
At baseline there were no significant differences between the groups in HDAC2 
activity in sputum (data not shown) or bronchoalveolar lavage macrophages (Figure 
3f). Following infection HDAC2 activity in the smoking controls and non-smoking 
controls did not change significantly from baseline, but tended to increase (Figure 3e 
and f). In the COPD subjects there was a trend towards reduced HDAC2 activity in 
both sputum (P=0.064) and bronchoalveolar lavage macrophages (P=0.098, Figure 
3e and f). Sputum HDAC2 activity was significantly lower in the COPD subjects 
compared to non-smokers on days 5 and 21 (P<0.05), and there was a trend 
towards lower levels of bronchoalveolar lavage HDAC2 activity during exacerbation 
compared to the non-smokers (P=0.095) and smokers (P=0.059).  
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Correlations  
Baseline HDAC2: Sputum macrophage HDAC2 activity at baseline correlated 
inversely with peak post-inoculation sputum virus load (P=0.022, r=-0.82),sputum NE 
(P=0.022, r=-0.81), CXCL8/IL-8 (P=0.047, r=-0.71) and TNF-α (P=0.028, r=-0.79) 
(Table 2). There were no relationships between baseline HDAC2 activity and 
outcomes following infection in the non-COPD subjects.  
Oxidative stress: In the COPD subjects peak sputum 8-isoprostane levels and 8-
OHdG levels during exacerbations correlated with each other (P=0.0068, r=0.82) 
and 8-OHdG correlated with peak sputum neutrophil elastase (P=0.0125, r=0.78) 
and sputum 3-NT levels (P=0.0016, r=0.83).  
Nitrosative stress: Peak sputum 3-NT and sputum nitrite levels during exacerbation 
correlated with each other (P=0.0037, r=0.85). Peak sputum 3-NT correlated with 
peak neutrophil elastase (P=0.0009, r=0.9) and peak sputum nitrite correlated with 
peak sputum inflammatory cell numbers (P=0.0125, r=0.778), neutrophil elastase 
(P=0.042, r=0.68) and neutrophil numbers (P=0.0096, r=0.8) (Table 3).  
HDAC2 activity: HDAC2 activity in bronchoalveolar lavage macrophages in COPD 
subjects during exacerbations correlated inversely with peak nasal lavage virus load 
(P=0.0096, r=-0.8), peak sputum GM-CSF (P=0.0499, r=-0.67), TNF-α (P=0.03, r=-
0.72), neutrophil elastase (P=0.0499, r=-0.67) and sputum nitrite levels (P=0.0125, 
r=-0.78) (Table 2). 
 
Rhinovirus infection of monocytes in vitro  
Rhinovirus infection of the monocytic cell line THP-1 resulted in up-regulation of the 
inflammatory cytokines IL-6 and CXCL8/IL-8 (Figure 4). Rhinovirus infection reduced 
expression of HDAC2 (both mRNA and protein) compared to non-infected cells 
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(Figure 4c and 4d), and reduced HDAC2 activity (Figure 4e). Levels of nitrosylated 
HDAC2 were increased post-infection compared to non-infected cells (Figure 4f). 
THP-1 cells were treated with N-acetylcysteine (NAC) in order to inhibit the actions 
of peroxynitrate18-20. Treatment of the THP-1 cells with NAC led to a dose-dependent 
reduction in IL-6 and CXCL8/IL-8, with significant reductions in inflammatory 
mediators observed at doses over 1mM (Figures 4g and 4h). 
Discussion 
Acute exacerbations are important events in the natural history of COPD, but their 
pathogenesis remains poorly understood. Prevention of exacerbations remains a key 
therapeutic goal but current treatments have only modest benefits and considerable 
adverse effects. Previous work from our group has demonstrated that experimental 
rhinovirus infection in COPD subjects induces respiratory symptoms, airflow 
obstruction and neutrophilic inflammation15. In the current study we provide novel 
evidence of the mechanisms of virus-induced COPD exacerbations and identify new 
potential therapeutic targets.  
Oxidative/nitrosative stress, airways inflammation and reduced HDAC activity are 
well described in stable COPD but their roles in COPD exacerbations are unclear. 
Some studies have reported increased inflammation and oxidative stress in 
exacerbations3,21-24, whereas others have reported no change compared to the 
stable state25-28. Increased numbers of 3-NT positive cells have been reported in 
COPD exacerbations21 and two studies reported that HDAC activity is unchanged in 
exacerbated COPD28,29. In these studies of naturally-occurring exacerbations there 
are numerous sources of variability that likely account for the discrepant results of 
these studies, including variations in exacerbation aetiology, timing of 
presentation/sampling after exacerbation onset, different treatments etc. that are 
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difficult to eliminate. Understanding the molecular pathways in COPD exacerbations 
is critical to developing new, more effective preventative and therapeutic strategies. 
Our model of COPD exacerbation permits repeated lower airway sampling in 
treatment-naïve subjects in a manner not possible with naturally-occurring 
exacerbations, thereby reducing variability and offering unique insights into the 
mechanisms of COPD exacerbations15,16,30,31. Moreover use of a human, as opposed 
to an animal model provides data that is more likely to be rapidly translated into new 
therapies. Using this model we measured markers of inflammation, oxidative and 
nitrosative stress and HDAC activity prior to and following rhinovirus infection.  
We previously reported that virus-induced exacerbations are associated with 
increased neutrophils, neutrophil elastase, and CXCL8/IL-815. In the current study we 
replicated these findings in a new cohort of subjects and, in addition, demonstrated 
that virus infection induces significant increases in the pro-inflammatory cytokines 
GM-CSF, TNF-α and IL-1β, and the protease MMP-9. Levels of 8-isoprostane (a 
marker of lipid peroxidation), 8-OHdG (a marker of hydroxyl radical damage to DNA), 
3-NT (a product of tyrosine nitration mediated by peroxynitrite) and nitrite were 
significantly increased in sputum in the COPD subjects, with only small, transient 
increases in non-COPD smokers. There were positive correlations between markers 
of nitrosative stress and inflammatory mediators in sputum. These data provide new 
evidence of a pathogenic role of oxidative and nitrosative stress in COPD 
exacerbations. Exacerbations are associated with accelerated loss of lung function32-
34 and nitrosative/oxidative stress35,36, neutrophil elastase37 and MMP-938 are all 
associated with airway remodelling and therefore these are potential mechanisms 
linking exacerbations with loss of lung function in COPD. 
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HDAC2 levels at baseline were not lower in the COPD subjects as has been 
reported previously in patients with COPD GOLD stages II and III8. Reduced HDAC2 
is most pronounced in severe COPD and therefore may not be present in subjects 
with GOLD stage II disease. Following rhinovirus infection there was a trend towards 
reduced HDAC2 activity in sputum and BAL macrophages in COPD subjects and 
HDAC activity correlated inversely with airways inflammation, virus load and nitrite 
levels. Nitrosylation of HDAC, followed by HDAC degradation is a mechanism of 
reduced HDAC2 activity39 and our in vitro data is the first report that virus infection 
induces nitrosylation of HDAC2. The inverse relationship between airway HDAC2 
activity and nitrite levels following virus infection suggests this is relevant in vivo also. 
Therefore nitrosylation of HDAC2 may link virus infection, oxidative/nitrosative 
stress, impaired HDAC2 activity and enhanced inflammation in COPD 
exacerbations.  
These results have a number of important implications for our understanding of the 
pathogenesis of COPD exacerbations and future therapeutic directions. 
Corticosteroids are used in COPD exacerbations despite modest clinical benefits 
and frequent adverse effects5,40. Reduced HDAC2 may contribute to corticosteroid 
resistance in stable COPD8 and our results suggest this is also relevant in 
exacerbated COPD. Thus enhancing HDAC2 activity through inhibiting virus-induced 
oxidative/nitrosative stress has the potential to improve the therapeutic effect of 
corticosteroids in COPD exacerbations, as well as having a direct anti-inflammatory 
effect itself. This warrants investigation in studies specifically designed to address 
this issue. The demonstration that oxidative/nitrosative stress and multiple 
inflammatory mediators and proteases are elevated in exacerbations may account 
for the lack of clinical benefit seen with inhibition of single mediators41-44, and casts 
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doubt on this as a valid therapeutic approach. N-acetylcysteine that is both an 
antioxidant and a peroxynitrite inhibitor demonstrated an anti-inflammatory effect in 
vitro and may also be effective in vivo. 
Reduced baseline HDAC2 activity in sputum macrophages was associated with 
greater virus loads post-infection; therefore reduced HDAC2 activity may also be 
linked to impaired antiviral responses. We observed significantly higher sputum virus 
loads in COPD subjects, confirming for the first time impaired antiviral immunity in 
COPD results in more severe lower respiratory virus infection. HDAC activity is 
required for an effective antiviral response to picornavirus infection45, therefore 
reduced HDAC activity may contribute to impaired antiviral host defence and 
increased severity of clinical illness following virus infections in COPD. 
Our study has a number of limitations that are inherent to experimental infection 
studies. The number of subjects was small and only subjects with moderate COPD 
were included, and therefore the findings may not be applicable to more severe 
patients. However as HDAC2 activity is further reduced8 and exacerbations more 
frequent in severe COPD2, we believe these mechanisms are likely to be even more 
relevant in more severe disease. Secondary bacterial infections did occur in some 
subjects30 but the numbers were too small to allow an analysis of the interactions 
between HDAC2 activity and bacteria (6 subjects with bacterial infection, 3 without). 
Whether changes in HDAC2 activity affect the ability of macrophages to clear 
bacteria is a subject of great interest and warrants further investigation. The smokers 
were significantly younger compared to the non-smokers but there were no 
significant differences in age between the COPD group and the 2 control groups and 
as the key comparisons were between the COPD and non-COPD subjects, we do 
not believe this affected the important results. Moreover Ito et al reported that age 
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had no effect on HDAC activity in bronchial biopsies8. However, ideally subsequent 
studies should use age-matched subjects whenever possible to remove this 
confounder. We used sputum to measure inflammatory meditors and cells and these 
do not reflect inflammation in the small airways. The main site of rhinovirus 
replication is epithelial cells rather than macrophages and therefore the significance 
of the relationship between HDAC2 levels in macrophages and virus load is unclear. 
The in vitro work was carried out in THP-1 cells rather than alveolar macrophages as 
these are difficult to obtain in large enough numbers to perform the necessary 
experiments. However the data obtained provides valid mechanistic information as to 
the potential mechanisms involved in macrophage responses to viral infection in 
COPD. 
In summary we have demonstrated induction of oxidative and nitrosative stress, 
reduced HDAC2 activity, increased inflammatory mediators and increased virus load 
in the airways following rhinovirus infection in COPD subjects. These results provide 
unique insights into the mechanisms of virus-induced COPD exacerbations and 
suggest novel therapeutic targets for the development of new targeted therapies in 
COPD. 
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Figure Legends 
Figure 1. Time course of inflammatory cells, neutrophil elastase and virus load in 
sputum during experimental rhinovirus infection. Panel A: Total sputum inflammatory 
cells (neutrophils, macrophages/monocytes, lymphocytes, eosinophils). Panel B: 
Sputum neutrophils. Panel C: Sputum neutrophil elastase. Panel D: Sputum virus 
load. All data are means ± SEM. *P<0.05, **P<0.01, ***P<0.001 vs. baseline. 
†
P<0.05, ††P<0.01 COPD vs. non-smokers. #P<0.01, ##P<0.01 COPD vs. smokers. 
 
Figure 2. Time course of inflammatory mediators in sputum during experimental 
rhinovirus infection in COPD. Panel A: Sputum IL-1β. Panel B: Sputum TNF-α. Panel 
C: Sputum GM-CSF. Panel D: Sputum CXCL8/IL-8. Panel E: Sputum MMP-9. All 
data are medians ± IQR. *P<0.05, **P<0.01, ***P<0.001 vs. baseline. †P<0.05, 
††
P<0.01 COPD vs. non-smokers.  
 
Figure 3. Time course of oxidative and nitrosative stress markers in sputum and 
HDAC2 activity in sputum and bronchoalveolar lavage macrophages during 
experimental rhinovirus infection. Panel A: Sputum 8-isoprostane. Panel B: Sputum 
8-hydroxy-2’-deoxyguanosine. Panel C: Sputum 3-nitrotyrosine. Panel D: Sputum 
nitrite. Panel E: Sputum macrophage HDAC2 activity –change from baseline. Panel 
F: Bronchoalveolar lavage macrophage HDAC2 activity. All data are medians ± IQR. 
*P<0.05, **P<0.01, ***P<0.001 vs. baseline. †P<0.05, ††P<0.01, †††P<0.001 COPD 
vs. non-smokers. #P<0.05, ##P<0.01, ###P<0.001 COPD vs. smokers. 
 
Figure 4. Rhinovirus infection of THP-1 cells in vitro. Panel A: Induction of IL-6 by 
rhinovirus in THP-1 cells. Panel B: Induction of CXCL-8 by rhinovirus in THP-1 cells. 
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Panel C: HDAC2 protein in THP-1 cells infected with rhinovirus. Panel D:  HDAC2 
RNA in THP-1 cells infected with rhinovirus protein. Panel E: HDAC2 activity in THP-
1 cells infected with rhinovirus. Panel F: HDAC2 nitrosylation in THP-1 cells infected 
with rhinovirus. Panel G: Inhibition of rhinovirus-induced IL-6 by N-acetylcysteine 
(NAC). Panel H: Inhibition of rhinovirus-induced CXCL8/IL-8 by NAC. *P<0.05 Data 
shows mean ± standard error of at least 3 independent experiments. 
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 Tables 
 
Non-smokers 
(N=11) 
Smokers 
(N=10) 
COPD 
(N=9) 
P values 
Age 
62.18 
(±1.62) 
52.50 
(±2.23) 
60.44 
(±3.17) 
P<0.05 SMK vs. 
NS 
Sex M:F 4:7 4:6 6:3 NS 
Current 
smokers 
0 10/10 8/9  
Smoking history  
(pack years) 
0 
32.1 
(±3.02) 
39.44 
(±3.25) 
NS 
FEV1 
(Litres) 
3.17 
(±0.17) 
3.24 
(±0.21) 
2.31 
(±0.13) 
P<0.05 COPD vs. 
NS, P<0.01 
COPD vs. SMK 
FEV1 
(% predicted) 
102.2 
(±3.34) 
96.60 
(±3.28) 
68.11 
(±1.58) 
P<0.0001 COPD 
vs. SMK and NS 
FEV1/FVC 
77.62 
(±1.09) 
78.04 
(±2.18) 
61.58 
(±1.80) 
P<0.0001 COPD 
vs. SMK and NS 
Table 1. Baseline clinical characteristics of study subjects. All data mean ± SEM. 
 
 Baseline sputum 
HDAC2 
Post-inoculation BAL 
macrophages HDAC2 
Peak sputum virus load 
 
P=0.022, r=-0.82 / 
Peak sputum neutrophil elastase 
 
P=0.022, r=-0.81 P=0.0499, r=-0.67 
Peak sputum CXCL8/IL-8 
 
P=0.047, r=-0.71 / 
Peak sputum TNF-α 
 
P=0.028, r=-0.79 P=0.03, r=-0.72 
Peak nasal lavage virus load 
 
/ P=0.0096, r=-0.8 
Peak sputum GM-CSF 
 
/ P=0.0499, r=-0.67 
Peak sputum nitrite 
 
/ P=0.0125, r=-0.78 
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Table 2. Correlations between baseline sputum HDAC2 levels and post-inoculation 
BAL macrophages HDAC2 levels and peak levels of sputum inflammatory mediators 
and virus load.  
 
 
Table 3. Correlations between peak levels of sputum inflammatory mediators, virus 
load, sputum cell counts and markers of oxidative and nitrosative stress in the COPD 
subjects. 8-IP – 8-isoprostane, 8-OHdG – 8-hydroxy-2’-deoxyguanosine, 3-NT – 3-
nitrotyrosine.  
 
Inflammatory 
mediators 
Virus load 
Inflammatory cells and neutrophil 
markers  
Oxidative stress Nitrosative stress 
Total cell 
count 
Neutrophils 
Neutrophil 
elastase 
8-IP 8-OHdG 3-NT Nitrite 
IL-1β NS NS 
P=0043 
r=07 
NS NS NS 
P=0031 
r=073 
P=0017 
r=078 
TNF-α NS 
P=0031 
r=073 
P=0016 
r=077 
P=0026 
r=075 
NS NS 
P=0017 
r=078 
P=0.0007 
r=093 
GM-CSF NS 
P=0021 
r=077 
P=002 
r=075 
NS NS NS NS 
P=00053 
r=083 
CXCL8 
/IL-8 
P=0.0096 
r=0.8 
P=00096 
r=08 
P=00072 
r=082 
NS NS NS NS 
P=005 
r=068 
MMP-9 NS 
P=00031 
r=088 
P=00025 
r=087 
NS NS NS 
P=00083 
r=083 
P=00004 
r=095 
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Materials and Methods 
Symptom scores 
Symptoms were assessed using diary cards that were completed on a daily basis 
from screening until 6 weeks post-inoculation. The scoring system for the lower 
respiratory symptoms of shortness of breath, cough, wheeze, sputum quantity and 
sputum quality was that used in our previous experimental infection studies and is 
shown in e-Table 1. The daily lower respiratory score was summated from the 
individual scores and a COPD exacerbation was defined as an increase in the lower 
respiratory score of at least 2 points over baseline for at least 2 consecutive days. 
For both upper and lower respiratory daily symptom scores the mean scores on days 
-6 to 0 were calculated and subtracted from subsequent daily scores to correct for 
baseline symptoms.  
 
Induced sputum 
Sputum was induced and processed using protocols used in our previous studies. A 
cell pellet was obtained and total inflammatory cell numbers (neutrophils, 
macrophages/monocytes, lymphocytes and eosinophils) counted. Cytospins were 
prepared and counted blind to study status to obtain differential cell counts. Cell 
counts were expressed as a percentage of at least 400 inflamm tory cells. 
 
Measurement of oxidative and nitrosative stress  
For each subject all the treatment days were coded and assayed blind on a single 96 
well plate, and all groups were assayed together in three plates, so the observed 
differences between the different groups are not linked to plate-to-plate variation. All 
the samples were assayed in a total of 3 plates over 3 days per target and there 
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were no observable variations between those 3 plates for standard curves and blank 
read-outs. Sputum nitrite levels were measured using the Griess assay which is 
based on formation of an azo dye by reaction of nitrite with the Griess reagent. All 
analysis was performed with the same batch of reagents, made in-house, stored at 
4oC in light protective containers. A nitrate standard curve was prepared using 
sodium nitrite (Sigma, UK) at concentrations from 0-1000µM (PBS alone). Briefly an 
equal volume of Griess reagents 1 (1% sulphanilamide (Sigma, UK) and 5% 
phosphoric acid (H3PO4)) & 2 (0.5% of napthylethyl-endiamide dihydrochloride 
(Sigma, UK)) were mixed and allowed to equilibrate, 100µL of standard or sample 
was added to duplicate wells of a 96 well plate before addition of 100µL complete 
(combined) Griess reagent and colorimetric values measured at 550nm read on a 
standard plate reader.  The lower limit of detection was 1µM. Data was analysed by 
linear regression against the standard curve.   
 
HDAC2 immunoprecipitation and activity 
A cell pellet as obtained from sputum and BAL and diluted with 3ml of macrophage 
media, distributed across wells of a modified polystyrene flat bottom adhesive culture 
plate (Falcon, Becton Dickinson, USA) and incubated for 2 hours at 37oC and 5% 
CO2 to facilitate macrophage separation by adhesion to the well base. After 2 hours 
adherent cells were washed from the well base using a cell scraper and centrifuged 
(18.8g for 7 minutes) to obtain a cell pellet which was stored immediately at –80oC. 
HDAC activity was measured using an HDAC activity assay (Cayman Chemicals, 
USA).  Briefly the protocol involved addition of radioimmunoprecipitation (RIPA) 
assay buffer to the macrophage pellet obtained from cellular adhesion. This was 
incubated before combination with the HDAC2 antibody and overnight mixing on a 
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sample roller. Magnetic beads were then added for 2 hours of incubation prior to 
bead removal. Analysis of HDAC2 activity was performed in the protein sample and 
the supernatant used to calculate total protein concentration using the bicinchoninic 
acid assay performed according to published methods1 and results of HDAC2 
activity corrected for sample protein levels. 
 
MesoScale D scovery 
The technique enables quantitative detection of between 1 and 9 mediators per well 
in a 96 well plate format using a Multi-spot® technique. This technology utilises a 
capture antibody attached to each spot within the well which enables measurement 
of multiple mediators simultaneously. Electrochemiluminescence of detection 
antibody is then recorded with an internal high sensitivity camera (Sector imager). 
Briefly, the protocol requires addition of 25µL of blocking solution before incubation. 
Following plate washing either sample or standard was added to the plate, followed 
by incubation and washing and addition of detection antibody. Finally read buffer 
was added and the plate passed through the Sector imager for reading. The lower 
limits of detection of the individual analytes were as follows: IL-1β (1.17pg/ml), 
CXCL8/IL-8 (0.6pg/ml), TNF-α (0.376pg/ml), CXCL10 (12pg/ml), GM-CSF 
(1.12pg/ml), MMP-9 (0.0988ng/ml). 
 
Rhinovirus in vitro infection of THP-1 cells  
THP-1 cells (a human monocytic cell line) were sub-cultured overnight in media 
containing 2% foetal calf serum. Rhinovirus 16 was prepared as previously 
described2 and cells were incubated with rhinovirus 16 for 1 hour. This was then 
replaced with fresh media and cells were collected at 24, 48, 72 and 96 hours post-
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infection. The levels of the cytokines IL-6 and CXCL8/IL-8 were measured in the 
supernatant using ELISA kits following manufacturer’s instructions (R&D systems, 
UK). HDAC2 protein was extracted using RIPA buffer and immunoprecipitated (IP) 
as described above. HDAC2 levels were quantitated by Western blot and 
standardised against the heavy chain of the (IP) antibody. 3-nitrotyrosine HDAC2 
levels were measured in IP-HDAC2 by Western Blot (antibody from Sigma, UK) with 
the 3-nitrotyrosine band standardised to HDAC2 levels.  
Total RNA was isolated from THP-1 cells using the RNeasy RNA extraction kit 
(Qiagen, UK). cDNA was made from quantified RNA by reverse transcription. 
HDAC2 mRNA expression levels were quantified by Real-Time PCR protocol using 
TaqMan (Applied Biosystems, UK). Each transcript was analysed by delta (∆)CT 
method (against baseline) and variations in cDNA concentrations between different 
samples was corrected using the housekeeping gene GNB2L1.  
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Supplementary Tables 
All subjects 
• Age 40-75 years. 
• No history of asthma or allergic rhinitis and not atopic on skin testing. 
• Absence of a current or previous history of bronchiectasis, carcinoma of the 
bronchus or other significant respiratory disease (other than COPD). 
• Absence of significant systemic disease. 
• No COPD exacerbation or respiratory tract infection within the previous eight 
weeks. 
• Serum antibodies to rhinovirus 16 at screening in a titre <1:2. 
• No treatment with antibiotics, oral, inhaled or nasal topical steroids, long-acting β-
agonists or tiotropium in the previous three months. 
 
COPD group 
• FEV1 50% - 79% predicted normal value and β-agonist reversibility <12%. 
• FEV1/FVC<70%. 
• Current or ex-smokers with at least 20 pack years cumulative smoking 
 
Smokers 
• FEV1≥80% predicted normal value. 
• FEV1/FVC>70%. 
• Current or ex-smokers with at least 20 pack years cumulative smoking 
 
Non-smokers 
• FEV1≥80% predicted normal value. 
• FEV1/FVC>70%. 
• Non-smokers  
e-Table 1. Inclusion and exclusion criteria for study subjects. 
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SYMPTOM 
SCORE 
0 1 2 3 4 
SHORTNESS 
OF BREATH 
Not breathless 
On moderate 
exertion 
On mild 
exertion 
On minimal         
exertion 
At rest 
WHEEZE No wheeze 
On moderate 
exertion 
On mild 
exertion 
On minimal         
exertion 
At rest 
COUGH No cough Mild Moderate Severe / 
SPUTUM 
QUANTITY 
None 
Minimal 
(<30mL) 
Moderate                                   
(30-100mL) 
Large 
(>100mL) 
/ 
SPUTUM 
QUALITY 
None Mucoid (clear) 
Mucopurulent 
(yellow) 
Purulent   
(green) 
/ 
e-Table 2. Scoring system for lower respiratory symptoms. 
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Results 
Supplementary Figures 
 
 
 
 
 
 
 
 
 
 
e-Figure 1. Time course of total lower respiratory scores following rhinovirus infection 
 
 
e-Figure 2. Time course of FEV1 following rhinovirus infection. All data are means ± 
SEM. *P<0.05, **P<0.01, vs. baseline. 
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e-Figure 3. Inflammatory mediators in bronchoalveolar lavage during experimental 
rhinovirus infection. 
 
 
 
Page 37 of 63
ScholarOne - http://mchelp.manuscriptcentral.com/gethelpnow/index.html - (434) 964-4100
CHEST
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Privileged Communication
 
Baseline Day 3 Day 5 Day 9 Day 12 Day 15 Day 21 Day 42 
Non-
Smokers 
2.02 
± 0.4 
1.41 
± 0.19 
1.51 
± 0.32 
2.18 
± 0.64 
3.22 
± 1.0 
1.43 
± 0.24 
1.03 
± 0.19 
1.04 
± 0.15 
Smokers 
1.72  
± 0.63 
1.61 
± 0.5 
1.74 
± 0.27 
5.96 
± 2.13 
2.06 
± 0.61 
2.60 
± 0.59 
2.41 
± 0.51 
3.42 
± 1.9 
COPD 
1.16 
± 0.21 
2.47 
± 0.58 
2.96 
± 0.92 
12.65 
± 4.66 
9.17 
± 4.14 
6.85 
± 1.89 
5.86 
± 4.1 
1.99 
± 0.56 
 
e-Table 3. Total inflammatory cell numbers in sputum (x 106/g sputum, mean ± SEM) 
 
 
 
Baseline Day 7 
Non-Smokers 
79.28 
(73.81 - 143) 
182.2 
(146.1 - 524.4) 
Smokers 
318.8 
(146.1 - 524.4) 
359.2 
(174.2 - 698.4) 
COPD 
144.7 
(88.03 - 630.9) 
353.4 
(141.6 - 511.6) 
 
e-Table 4. Total inflammatory cell numbers in bronchoalveolar lavage (x106/L, 
median and IQR) 
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Text 2948 
Abstract 236 
 
Oxidative and nitrosative stress and histone deacetylase-2 activity 
in exacerbations of Chronic Obstructive Pulmonary Disease  
 
Short title: Oxidative stress and HDAC2 in COPD exacerbations 
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Abstract 
Background   
Respiratory virus infections are commonly associated with COPD exacerbations but 
little is known about the mechanisms linking virus infection to exacerbations. 
Pathogenic mechanisms in stable COPD include oxidative and nitrosative stress and 
reduced activity of histone deacetylase-2 (HDAC2) but their roles in COPD 
exacerbations is unknown. We investigated oxidative/nitrosative stress and HDAC2 
in COPD exacerbations using experimental rhinovirus infection.  
Methods  
9 subjects with COPD (GOLD stage II), 10 smokers and 11 non-smokers were 
successfully infected with rhinovirus. Markers of oxidative and nitrosative-stress 
associated cellular damage, inflammatory mediators and proteases were measured 
in sputum, and HDAC2 activity measured in sputum and bronchoalveolar 
macrophages. In an in vitro model monocyte derived THP-1 cells were infected with 
rhinovirus and nitrosylation and activity of HDAC2 measured.  
Results 
Rhinovirus infection induced significant increases i  airways inflammation and 
markers of oxidative and nitrosative stress in COPD subjects. Oxidative/nitrosative 
stress markers correlated with virus load and inflammatory markers. Macrophage 
HDAC2 activity was reduced during exacerbation and correlated inversely with virus 
load, inflammatory markers and nitrosative stress. Sputum macrophage HDAC2 
activity pre-infection was inversely associated with sputum virus load and 
inflammatory makers during exacerbation. Rhinovirus infection of monocytes 
induced nitrosylation of HDAC2 and reduced HDAC2 activity, inhibition of 
oxidative/nitrosative stress inhibited rhinovirus-induced inflammatory cytokines.  
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Conclusions  
Oxidative and nitrosative stress, airways inflammation and impaired HDAC2 may be 
important mechanisms of virus-induced COPD exacerbations. Therapies targeting 
these mechanisms offer potential new treatments for COPD exacerbations. 
 
 
Abbreviations List 
3-NT   3-nitrotyrosine 
8-OHdG  8-hydroxy-2’-deoxyguanosine 
ATS   American Thoracic Society 
COPD   Chronic obstructive pulmonary disease  
ERS   European Respiratory Society 
FEV1   Forced expiratory volume in 1 second 
FVC   Forced vital capacity 
GM-CSF  Granulocyte-macrophage colony stimulating factor 
GOLD   Global Initiative for Obstructive Lung Disease 
HDAC2  Histone deacetylase-2  
IL-   Interleukin 
MMP-9  Matrix metalloprotease-9 
NAC   N-acetylcysteine 
NE   Neutrophil elastase 
RNS   Reactive nitrogen species  
ROS   Reactive oxygen species  
TCID50  Tissue culture infective dose50  
TNF-α   Tumour necrosis factor-alpha 
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Introduction 
Chronic obstructive pulmonary disease (COPD) is a rapidly growing global 
epidemic1. COPD exacerbations cause impaired quality of life, accelerated loss of 
lung function, and enormous healthcare costs2. Most exacerbations are a 
consequence of viral and/or bacterial infections, the most common viruses identified 
are rhinoviruses3 but the mechanisms of virus-induced exacerbations remain 
unclear4. Current therapies for exacerbations consist of corticosteroids and 
antibiotics but these are not very effective, have frequent adverse effects and are 
focused on bacterial exacerbations5,6. New treatments are urgently needed and 
developing these requires a better understanding of the mechanisms of COPD 
exacerbations.  
Pathogenic mechanisms in stable COPD include oxidative and nitrosative stress and 
reduced expression of the anti-inflammatory enzyme histone deacetylase-2 
(HDAC2)7-9. High levels of reactive oxygen species (ROS) and reactive nitrogen 
species (RNS) are generated in COPD resulting in induction of pro-inflammatory 
cytokines and chemokines, mucous hypersecretion, activation of proteases and 
damage to cellular components10. Histone deacetylases remove acetyl groups on 
histones and influence gene expression. HDAC2 suppresses inflammatory gene 
expression and is reduced in alveolar macrophages and lung tissue in COPD, and 
this is believed to be a key mechanism of corticosteroid resistance in COPD8,11. 
Nitrosylation of tyrosine residues on HDAC2 by peroxynitrite results in its 
inactivation12 and ROS activate phosphoinositide 3-kinase leading to 
phosphorylation and inactivation of HDAC213. Therefore oxidative and nitrosative 
stress exert pro-inflammatory effects both through direct induction of inflammatory 
mediators and reduction of the anti-inflammatory action of HDAC2. 
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The roles of oxidative and nitrosative stress and HDAC2 in COPD exacerbations are 
unclear. We have previously demonstrated that experimental rhinovirus infection 
induces symptoms, airflow obstruction and airways inflammation in COPD subjects14-
16
. We hypothesized that oxidative and nitrosative stress are increased and HDAC2 
activity reduced in virus-induced COPD exacerbations.  
 
Methods 
Study design 
Ethical approval for the study was obtained from St Mary’s Local Research Ethics 
Committee (study number 07/H0712/138) and informed consent obtained from all 
subjects. COPD subjects (GOLD stage II) and smokers with normal lung function 
were recruited according the criteria established in our previous study 
(Supplementary Table 1)15, together with non-smokers with normal lung function. 
The COPD patients were receiving no inhaled corticosteroids, long-acting regular 
bronchodilators or oral corticosteroids. Baseline samples of induced sputum and 
bronchoalveolar lavage were obtained approximately 14 days prior to infection and 
subjects were inoculated with 10 TCID50 of rhinovirus 16 on day 0 as described 
previously15. Sputum sampling was repeated on subsequent visits on days 3, 5, 9, 
12, 15, 21, and 42 post-infection and bronchoscopy on day 7. Respiratory symptoms 
were recorded daily using diary cards as per our previous studies. A COPD 
exacerbation was defined as an increase in the total lower respiratory score of at 
least 2 points over baseline for at least 2 consecutive days. 
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Sputum assessments 
8-hydroxy-2’-deoxyguanosine (8-OHdG), a marker of hydroxyl radical damage to 
DNA, 8-isoprostane, a marker of lipid peroxidation and 3-nitrotyrosine (3-NT) a 
product of tyrosine nitration mediated by peroxynitrite were measured in sputum 
supernatants using commercially available enzyme immunoassays (Cayman 
Chemical, Ann Arbor, MI, USA) according to the manufacturer’s instructions. Sputum 
nitrite levels were measured using the Griess assay. The Meso Scale Discovery 
(MSD) platform (Maryland, USA) was used to measure inflammatory mediators in 
sputum and bronchoalveolar lavage supernatants. The mediators measured were 
the pro-inflammatory cytokines IL-1β, TNF-α, and GM-CSF, the neutrophil 
chemokine CXCL8/IL-8 and the protease matrix metalloprotease-9 (MMP-9). 
Neutrophil elastase was measured using an enzyme-linked immunosorbent assay 
according to the manufacturers’ instructions (Immunodiagnostik, Benshein, 
Germany). Further details are provided in the e-Appendix.   
 
HDAC2 immunoprecipitation and activity 
The HDAC2 isoenzyme was isolated from macrophage pellets obtained from sputum 
and bronchoalveolar lavage samples. Immunoprecipitation using a HDAC2 antibody 
(Insight Biotect, UK) and PureProteome® Protein A magnetic beads (Millipore, USA) 
was performed.  HDAC activity was measured using a HDAC activity assay (Cayman 
Chemicals, USA) the details of which are provided in the e-Appendix. 
Details of the experimental protocols of the in vitro infection of THP-1 cells (a human 
monocyte cell line) to further investigate the effects of rhinovirus infection on HDAC2 
are provided in the e-Appendix.  
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Statistical analysis 
Data are presented as either means or median, and changes from baseline were 
analysed using repeated measures ANOVA or Friedman’s test and differences 
between groups using Holm-Sidak’s multiple comparisons test or the Kruskal-
Wallace test. Correlations between data sets were examined using Spearman's rank 
correlation coefficient. Correlations were examined using peak post-inoculation 
values as in a dynamic and evolving clinical event such as a respiratory infection the 
temporal relationships between the induction of the different markers was variable 
between individual subjects, and using set days may miss relationships where timing 
of events varied. Differences were considered significant for all statistical tests at P 
values of less than 0.05. All reported P values are two-sided. Analysis was 
performed using GraphPad Prism version 6.00 for Windows (GraphPad Software, 
San Diego USA). 
 
Results 
Study subjects 
The clinical characteristics of the subjects successfully infected with rhinovirus 16 
are shown in Table 1. Subjects were age and sex matched between the COPD 
subjects and both control groups, but the non-smokers were older than the smoking 
controls. Cigarette smoke exposure between smoking controls and COPD subjects 
was matched for pack year history.  
 
Clinical and inflammatory responses  
Symptoms and lung function: All COPD subjects experienced an exacerbation 
following rhinovirus infection (e-Figure 1)15. All exacerbations were Level I according 
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to the ATS/ERS severity classification17. FEV1 fell significantly from baseline in the 
COPD subjects on days 3, 5 (P<0.05), 9 (P<0.01), 12 (P<0.05) and 15 (P<0.01), 
with a maximum fall of 250mL (12.92%) on day 15. There were no significant falls 
from baseline in FEV1 in the control groups (e-Figure 2).  
Sputum inflammatory cells, neutrophil elastase and virus load: In the COPD 
subjects sputum inflammatory cells were significantly increased over baseline on day 
9, and were significantly higher compared to the non-smokers on days 9 and 15 
(Figure 1a). There was no significant change from baseline in the smokers and the 
non-smokers. Sputum neutrophils increased significantly from baseline in the COPD 
subjects on day 9 and were significantly higher compared to the smokers on day 12 
(Figure 1b). There were no significant changes in numbers of neutrophils in either 
control group, nor in numbers of macrophages, lymphocytes, or eosinophils in any 
group. Levels of neutrophil elastase in sputum increased from baseline on days 9 
and 15 in the COPD subjects and were significantly higher in the COPD group 
compared to controls on day 5(Figure 1c). 
Sputum virus load was increased from baseline on days 3–15 in the COPD subjects, 
on days 5 and 9 in the smokers and on days 3 and 9 in non-smokers (Figure 1d). 
Sputum virus load was significantly higher in the COPD group compared to both 
control groups on day 12 and compared to the non-smokers on day 15.  
Sputum inflammatory mediators: In the COPD subjects there were significant 
increases from baseline in IL-1β, GM-CSF, CXCL8/IL-8, TNF-α, and MMP-9 in 
sputum (Figure 2). There was no significant induction of inflammatory mediators in 
the non-COPD subjects apart from IL-1β on day 9 and GM-CSF on day 21 in the 
smokers. Sputum mediator levels were significantly higher in the COPD subjects 
compared to the non-smokers on days 9 and 15 and for some mediators on days 5, 
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12, and 21. Levels of inflammatory mediators in bronchoalveolar lavage both at 
baseline and post-inoculation were generally lower than in sputum and are shown in 
the Supplementary Index. Correlations between sputum inflammatory mediators, 
inflammatory cells and virus load in the COPD subjects are shown in Table 2. 
Oxidative and nitrosative stress: Prior to infection sputum 8-OHdG levels were 
higher in the COPD group compared to the smokers (P<0.05) and 3-NT levels were 
higher in the COPD group compared to both non-smokers (P<0.05) and smokers 
(P<0.001), with no differences between the groups in baseline levels of nitrite or 8-
isoprostane (Figure 3). Markers of oxidative and nitrosative stress were all 
significantly induced following rhinovirus infection in COPD subjects with much 
smaller induction seen in the smokers and were significantly higher in the COPD 
subjects compared to the non-COPD subjects (Figure 3 a-d).  
 
Macrophage HDAC2 activity  
At baseline there were no significant differences between the groups in HDAC2 
activity in sputum (data not shown) or bronchoalveolar lavage macrophages (Figure 
3f). Following infection HDAC2 activity in the smoking controls and non-smoking 
controls did not change significantly from baseline, but tended to increase (Figure 3e 
and f). In the COPD subjects there was a trend towards reduced HDAC2 activity in 
both sputum (P=0.064) and bronchoalveolar lavage macrophages (P=0.098, Figure 
3e and f). Sputum HDAC2 activity was significantly lower in the COPD subjects 
compared to non-smokers on days 5 and 21 (P<0.05), and there was a trend 
towards lower levels of bronchoalveolar lavage HDAC2 activity during exacerbation 
compared to the non-smokers (P=0.095) and smokers (P=0.059).  
 
Page 50 of 63
ScholarOne - http://mchelp.manuscriptcentral.com/gethelpnow/index.html - (434) 964-4100
CHEST
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Privileged Communication
- 12 - 
 
Correlations  
Baseline HDAC2: Sputum macrophage HDAC2 activity at baseline correlated 
inversely with peak post-inoculation sputum virus load (P=0.022, r=-0.82),sputum NE 
(P=0.022, r=-0.81), CXCL8/IL-8 (P=0.047, r=-0.71) and TNF-α (P=0.028, r=-0.79) 
(Table 2). There were no relationships between baseline HDAC2 activity and 
outcomes following infection in the non-COPD subjects.  
Oxidative stress: In the COPD subjects peak sputum 8-isoprostane levels and 8-
OHdG levels during exacerbations correlated with each other (P=0.0068, r=0.82) 
and 8-OHdG correlated with peak sputum neutrophil elastase (P=0.0125, r=0.78) 
and sputum 3-NT levels (P=0.0016, r=0.83).  
Nitrosative stress: Peak sputum 3-NT and sputum nitrite levels during exacerbation 
correlated with each other (P=0.0037, r=0.85). Peak sputum 3-NT correlated with 
peak neutrophil elastase (P=0.0009, r=0.9) and peak sputum nitrite correlated with 
peak sputum inflammatory cell numbers (P=0.0125, r=0.778), neutrophil elastase 
(P=0.042, r=0.68) and neutrophil numbers (P=0.0096, r=0.8) (Table 3).  
HDAC2 activity: HDAC2 activity in bronchoalveolar lavage macrophages in COPD 
subjects during exacerbations correlated inversely with peak nasal lavage virus load 
(P=0.0096, r=-0.8), peak sputum GM-CSF (P=0.0499, r=-0.67), TNF-α (P=0.03, r=-
0.72), neutrophil elastase (P=0.0499, r=-0.67) and sputum nitrite levels (P=0.0125, 
r=-0.78) (Table 2). 
 
Rhinovirus infection of monocytes in vitro  
Rhinovirus infection of the monocytic cell line THP-1 resulted in up-regulation of the 
inflammatory cytokines IL-6 and CXCL8/IL-8 (Figure 4). Rhinovirus infection reduced 
expression of HDAC2 (both mRNA and protein) compared to non-infected cells 
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(Figure 4c and 4d), and reduced HDAC2 activity (Figure 4e). Levels of nitrosylated 
HDAC2 were increased post-infection compared to non-infected cells (Figure 4f). 
THP-1 cells were treated with N-acetylcysteine (NAC) in order to inhibit the actions 
of peroxynitrate18-20. Treatment of the THP-1 cells with NAC led to a dose-dependent 
reduction in IL-6 and CXCL8/IL-8, with significant reductions in inflammatory 
mediators observed at doses over 1mM (Figures 4g and 4h). 
Discussion 
Acute exacerbations are important events in the natural history of COPD, but their 
pathogenesis remains poorly understood. Prevention of exacerbations remains a key 
therapeutic goal but current treatments have only modest benefits and considerable 
adverse effects. Previous work from our group has demonstrated that experimental 
rhinovirus infection in COPD subjects induces respiratory symptoms, airflow 
obstruction and neutrophilic inflammation15. In the current study we provide novel 
evidence of the mechanisms of virus-induced COPD exacerbations and identify new 
potential therapeutic targets.  
Oxidative/nitrosative stress, airways inflammation and reduced HDAC activity are 
well described in stable COPD but their roles in COPD exacerbations are unclear. 
Some studies have reported increased inflammation and oxidative stress in 
exacerbations3,21-24, whereas others have reported no change compared to the 
stable state25-28. Increased numbers of 3-NT positive cells have been reported in 
COPD exacerbations21 and two studies reported that HDAC activity is unchanged in 
exacerbated COPD28,29. In these studies of naturally-occurring exacerbations there 
are numerous sources of variability that likely account for the discrepant results of 
these studies, including variations in exacerbation aetiology, timing of 
presentation/sampling after exacerbation onset, different treatments etc. that are 
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difficult to eliminate. Understanding the molecular pathways in COPD exacerbations 
is critical to developing new, more effective preventative and therapeutic strategies. 
Our model of COPD exacerbation permits repeated lower airway sampling in 
treatment-naïve subjects in a manner not possible with naturally-occurring 
exacerbations, thereby reducing variability and offering unique insights into the 
mechanisms of COPD exacerbations15,16,30,31. Moreover use of a human, as opposed 
to an animal model provides data that is more likely to be rapidly translated into new 
therapies. Using this model we measured markers of inflammation, oxidative and 
nitrosative stress and HDAC activity prior to and following rhinovirus infection.  
We previously reported that virus-induced exacerbations are associated with 
increased neutrophils, neutrophil elastase, and CXCL8/IL-815. In the current study we 
replicated these findings in a new cohort of subjects and, in addition, demonstrated 
that virus infection induces significant increases in the pro-inflammatory cytokines 
GM-CSF, TNF-α and IL-1β, and the protease MMP-9. Levels of 8-isoprostane (a 
marker of lipid peroxidation), 8-OHdG (a marker of hydroxyl radical damage to DNA), 
3-NT (a product of tyrosine nitration mediated by peroxynitrite) and nitrite were 
significantly increased in sputum in the COPD subjects, with only small, transient 
increases in non-COPD smokers. There were positive correlations between markers 
of nitrosative stress and inflammatory mediators in sputum. These data provide new 
evidence of a pathogenic role of oxidative and nitrosative stress in COPD 
exacerbations. Exacerbations are associated with accelerated loss of lung function32-
34
 and nitrosative/oxidative stress35,36, neutrophil elastase37 and MMP-938 are all 
associated with airway remodelling and therefore these are potential mechanisms 
linking exacerbations with loss of lung function in COPD. 
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HDAC2 levels at baseline were not lower in the COPD subjects as has been 
reported previously in patients with COPD GOLD stages II and III8. Reduced HDAC2 
is most pronounced in severe COPD and therefore may not be present in subjects 
with GOLD stage II disease. Following rhinovirus infection there was a trend towards 
reduced HDAC2 activity in sputum and BAL macrophages in COPD subjects and 
HDAC activity correlated inversely with airways inflammation, virus load and nitrite 
levels. Nitrosylation of HDAC, followed by HDAC degradation is a mechanism of 
reduced HDAC2 activity39 and our in vitro data is the first report that virus infection 
induces nitrosylation of HDAC2. The inverse relationship between airway HDAC2 
activity and nitrite levels following virus infection suggests this is relevant in vivo also. 
Therefore nitrosylation of HDAC2 may link virus infection, oxidative/nitrosative 
stress, impaired HDAC2 activity and enhanced inflammation in COPD 
exacerbations.  
These results have a number of important implications for our understanding of the 
pathogenesis of COPD exacerbations and future therapeutic directions. 
Corticosteroids are used in COPD exacerbations despite modest clinical benefits 
and frequent adverse effects5,40. Reduced HDAC2 may contribute to corticosteroid 
resistance in stable COPD8 and our results suggest this is also relevant in 
exacerbated COPD. Thus enhancing HDAC2 activity through inhibiting virus-induced 
oxidative/nitrosative stress has the potential to improve the therapeutic effect of 
corticosteroids in COPD exacerbations, as well as having a direct anti-inflammatory 
effect itself. This warrants investigation in studies specifically designed to address 
this issue. The demonstration that oxidative/nitrosative stress and multiple 
inflammatory mediators and proteases are elevated in exacerbations may account 
for the lack of clinical benefit seen with inhibition of single mediators41-44, and casts 
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doubt on this as a valid therapeutic approach. N-acetylcysteine that is both an 
antioxidant and a peroxynitrite inhibitor demonstrated an anti-inflammatory effect in 
vitro and may also be effective in vivo. 
Reduced baseline HDAC2 activity in sputum macrophages was associated with 
greater virus loads post-infection; therefore reduced HDAC2 activity may also be 
linked to impaired antiviral responses. We observed significantly higher sputum virus 
loads in COPD subjects, confirming for the first time impaired antiviral immunity in 
COPD results in more severe lower respiratory virus infection. HDAC activity is 
required for an effective antiviral response to picornavirus infection45, therefore 
reduced HDAC activity may contribute to impaired antiviral host defence and 
increased severity of clinical illness following virus infections in COPD. 
Our study has a number of limitations that are inherent to experimental infection 
studies. The number of subjects was small and only subjects with moderate COPD 
were included, and therefore the findings may not be applicable to more severe 
patients. However as HDAC2 activity is further reduced8 and exacerbations more 
frequent in severe COPD2, we believe these mechanisms are likely to be even more 
relevant in more severe disease. Secondary bacterial infections did occur in some 
subjects30 but the numbers were too small to allow an analysis of the interactions 
between HDAC2 activity and bacteria (6 subjects with bacterial infection, 3 without). 
Whether changes in HDAC2 activity affect the ability of macrophages to clear 
bacteria is a subject of great interest and warrants further investigation. The smokers 
were significantly younger compared to the non-smokers but there were no 
significant differences in age between the COPD group and the 2 control groups and 
as the key comparisons were between the COPD and non-COPD subjects, we do 
not believe this affected the important results. Moreover Ito et al reported that age 
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had no effect on HDAC activity in bronchial biopsies8. However, ideally subsequent 
studies should use age-matched subjects whenever possible to remove this 
confounder. We used sputum to measure inflammatory meditors and cells and these 
do not reflect inflammation in the small airways. The main site of rhinovirus 
replication is epithelial cells rather than macrophages and therefore the significance 
of the relationship between HDAC2 levels in macrophages and virus load is unclear. 
The in vitro work was carried out in THP-1 cells rather than alveolar macrophages as 
these are difficult to obtain in large enough numbers to perform the necessary 
experiments. However the data obtained provides valid mechanistic information as to 
the potential mechanisms involved in macrophage responses to viral infection in 
COPD. 
In summary we have demonstrated induction of oxidative and nitrosative stress, 
reduced HDAC2 activity, increased inflammatory mediators and increased virus load 
in the airways following rhinovirus infection in COPD subjects. These results provide 
unique insights into the mechanisms of virus-induced COPD exacerbations and 
suggest novel therapeutic targets for the development of new targeted therapies in 
COPD. 
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Figure Legends 
Figure 1. Time course of inflammatory cells, neutrophil elastase and virus load in 
sputum during experimental rhinovirus infection. Panel A: Total sputum inflammatory 
cells (neutrophils, macrophages/monocytes, lymphocytes, eosinophils). Panel B: 
Sputum neutrophils. Panel C: Sputum neutrophil elastase. Panel D: Sputum virus 
load. All data are means ± SEM. *P<0.05, **P<0.01, ***P<0.001 vs. baseline. 
†P<0.05, ††P<0.01 COPD vs. non-smokers. #P<0.01, ##P<0.01 COPD vs. smokers. 
 
Figure 2. Time course of inflammatory mediators in sputum during experimental 
rhinovirus infection in COPD. Panel A: Sputum IL-1β. Panel B: Sputum TNF-α. Panel 
C: Sputum GM-CSF. Panel D: Sputum CXCL8/IL-8. Panel E: Sputum MMP-9. All 
data are medians ± IQR. *P<0.05, **P<0.01, ***P<0.001 vs. baseline. †P<0.05, 
††P<0.01 COPD vs. non-smokers.  
 
Figure 3. Time course of oxidative and nitrosative stress markers in sputum and 
HDAC2 activity in sputum and bronchoalveolar lavage macrophages during 
experimental rhinovirus infection. Panel A: Sputum 8-isoprostane. Panel B: Sputum 
8-hydroxy-2’-deoxyguanosine. Panel C: Sputum 3-nitrotyrosine. Panel D: Sputum 
nitrite. Panel E: Sputum macrophage HDAC2 activity –change from baseline. Panel 
F: Bronchoalveolar lavage macrophage HDAC2 activity. All data are medians ± IQR. 
*P<0.05, **P<0.01, ***P<0.001 vs. baseline. †P<0.05, ††P<0.01, †††P<0.001 COPD 
vs. non-smokers. #P<0.05, ##P<0.01, ###P<0.001 COPD vs. smokers. 
 
Figure 4. Rhinovirus infection of THP-1 cells in vitro. Panel A: Induction of IL-6 by 
rhinovirus in THP-1 cells. Panel B: Induction of CXCL-8 by rhinovirus in THP-1 cells. 
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Panel C: HDAC2 protein in THP-1 cells infected with rhinovirus. Panel D:  HDAC2 
RNA in THP-1 cells infected with rhinovirus protein. Panel E: HDAC2 activity in THP-
1 cells infected with rhinovirus. Panel F: HDAC2 nitrosylation in THP-1 cells infected 
with rhinovirus. Panel G: Inhibition of rhinovirus-induced IL-6 by N-acetylcysteine 
(NAC). Panel H: Inhibition of rhinovirus-induced CXCL8/IL-8 by NAC. *P<0.05 Data 
shows mean ± standard error of at least 3 independent experiments. 
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 Tables 
 Non-smokers 
(N=11) 
Smokers 
(N=10) 
COPD 
(N=9) P values 
Age 62.18 (±1.62) 
52.50 
(±2.23) 
60.44 
(±3.17) 
P<0.05 SMK vs. 
NS 
Sex M:F 4:7 4:6 6:3 NS 
Current 
smokers 0 10/10 8/9  
Smoking history  
(pack years) 0 
32.1 
(±3.02) 
39.44 
(±3.25) NS 
FEV1 
(Litres) 
3.17 
(±0.17) 
3.24 
(±0.21) 
2.31 
(±0.13) 
P<0.05 COPD vs. 
NS, P<0.01 
COPD vs. SMK 
FEV1 
(% predicted) 
102.2 
(±3.34) 
96.60 
(±3.28) 
68.11 
(±1.58) 
P<0.0001 COPD 
vs. SMK and NS 
FEV1/FVC 77.62 (±1.09) 
78.04 
(±2.18) 
61.58 
(±1.80) 
P<0.0001 COPD 
vs. SMK and NS 
Table 1. Baseline clinical characteristics of study subjects. All data mean ± SEM. 
 
 Baseline sputum 
HDAC2 
Post-inoculation BAL 
macrophages HDAC2 
Peak sputum virus load 
 
P=0.022, r=-0.82 / 
Peak sputum neutrophil elastase 
 
P=0.022, r=-0.81 P=0.0499, r=-0.67 
Peak sputum CXCL8/IL-8 
 
P=0.047, r=-0.71 / 
Peak sputum TNF-α 
 
P=0.028, r=-0.79 P=0.03, r=-0.72 
Peak nasal lavage virus load 
 
/ P=0.0096, r=-0.8 
Peak sputum GM-CSF 
 
/ P=0.0499, r=-0.67 
Peak sputum nitrite 
 
/ P=0.0125, r=-0.78 
Page 62 of 63
ScholarOne - http://mchelp.manuscriptcentral.com/gethelpnow/index.html - (434) 964-4100
CHEST
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Privileged Communication
- 24 - 
 
Table 2. Correlations between baseline sputum HDAC2 levels and post-inoculation 
BAL macrophages HDAC2 levels and peak levels of sputum inflammatory mediators 
and virus load.  
 
 
Table 3. Correlations between peak levels of sputum inflammatory mediators, virus 
load, sputum cell counts and markers of oxidative and nitrosative stress in the COPD 
subjects. 8-IP – 8-isoprostane, 8-OHdG – 8-hydroxy-2’-deoxyguanosine, 3-NT – 3-
nitrotyrosine.  
 
Inflammatory 
mediators Virus load 
Inflammatory cells and neutrophil 
markers  Oxidative stress Nitrosative stress 
Total cell 
count Neutrophils 
Neutrophil 
elastase 8-IP 8-OHdG 3-NT Nitrite 
IL-1β NS NS P=0·043 r=0·7 NS NS NS 
P=0·031 
r=0·73 
P=0·017 
r=0·78 
TNF-α NS P=0·031 r=0·73 
P=0·016 
r=0·77 
P=0·026 
r=0·75 NS NS 
P=0·017 
r=0·78 
P=0·.0007 
r=0·93 
GM-CSF NS P=0·021 r=0·77 
P=0·02 
r=0·75 NS NS NS NS 
P=0·0053 
r=0·83 
CXCL8 
/IL-8 
P=0.0096 
r=0.8 
P=0·0096 
r=0·8 
P=0·0072 
r=0·82 NS NS NS NS 
P=0·05 
r=0·68 
MMP-9 NS P=0·0031 r=0·88 
P=0·0025 
r=0·87 NS NS NS 
P=0·0083 
r=0·83 
P=0·0004 
r=0·95 
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